Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы: реабилитация и вторичная профилактика

10. Список основной литературы

  1. Аронов Д.М. Реабилитация больных, перенесших инфаркт миокарда на диспансерно-поликлиническом этапе. Методи- ческие рекомендации. М.: МЗ СССР, 1983.
  2. Аронов Д.М., Арутюнов Г.П., Белененков Ю.Н. и др. Согласованное мнение экспертов о целесообразности использования миокардиального цитопротектора в комплексной терапии больных с хроническими формами ишемической болезни сердца. Кардиосоматика. 2012; 2: 58–60.
  3. Аронов Д.М., Бубнова М.Г., Новикова Н.К. и др. Современные методы реабилитации больных ИБС на постстационарном (диспансерно-поликлиническом) этапе. Методические рекомендации, 2003.
  4. Аронов Д.М., Красницкий В.Б., Бубнова М.Г. и др. Физические тренировки в комплексной реабилитации и вторичной профилактике на амбулаторно-поликлиническом этапе у больных ишемической болезнью сердца после острых коронарных осложнений. Российское кооперативное исследование. Кардио- логия. 2006; 9: 33–8.
  5. Аронов Д.М., Новикова Н.К., Зволинская Е.Ю. и др. Физические тренировки больных ИБС в сочетании с сахарным диабетом второго типа. Методические рекомендации. М., 1996.
  6. Аронов Д.М., Тартаковский Л.Б., Новикова Н.К. Значение триметазидина в реабилитации больных после инфаркта миокарда. Кардиология. 2002; 42 (2): 14–20.
  7. Аронов Д.М., Шарфнадель М.Г. Сравнительная оценка эффек- тивности различных методов физических тренировок боль- ных, перенесших инфаркт миокарда. Бюллетень ВКНЦ. 1985; 2: 76–81.
  8. Арутюнов Г.П., Евзерихина А.В., Рылова А.К., Лобзева В.И. Кли- ническая эффективность разных форм непрерывного образо- вания пациентов, страдающих хронической сердечной недо- статочностью. Кардиосоматика. 2013; 1: 55–61.
  9. Барбараш О.Л., Лебедева Н.Б., Жукова Е.Л., Барбараш Л.С. Эф- фективность программы поведенческой реабилитации у больных инфарктом миокарда в зависимости от типа коро- нарного поведения. Кардиология. 2003; 41 (12): 73–81.
  10. Бойцов С.А., Чучалин А.Г. Российские рекомендации по про- филактике хронических неинфекционных заболеваний, 2013.
  11. Болдуева С.А., Шабров А.В., Монова И.А. и др. Клинико-психо- логические факторы, влияющие на риск внезапной смерти у больных, перенесших инфаркт миокарда. Кардиоваскулярная терапия. 2007; 7: 59–68.
  12. Бубнова М.Г., Аронов Д.М., Перова Н.В., Зволинская Е.Ю. Физические нагрузки и атеросклероз: влияние динамических нагрузок разной интенсивности на показатели липид-транспортной системы и углеводного обмена у больных коронарной болезнью сердца и сахарным диабетом 2 типа. Кардиология. 2005; 11: 33–40.
  13. Ефремушкин Г.Г., Антропова О.Н., Осипова И.В. Физическая реабилитация в комплексной терапии больных с низким сердечным выбросом. Тер. архив. 2003; 75 (12): 50–4.
  14. Лямина Н.П., Котельникова Е.В. Компьютерные технологии в организации реабилитационных мероприятий в первичном звене здравоохранения у больных ишемической болезнью сердца. Здравоохранение Российской Федерации. 2010; 5: 32–5.
  15. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) 2013. Сердечная недостаточность. 2013; 14 (7): 379–472.
  16. Николаева Л.Ф., Аронов Д.М. Реабилитация больных ишемической болезнью сердца (Руководство для врачей). М.: Медицина, 1988.
  17. Оганов Р.Г., Деев А.Д., Жуковский Г.С. Влияние курения на смертность от хронических неинфекционных заболеваний по результатам проспективного исследования. Проф. забол. и укрепл. здоровья. 1998; 3: 13–5.
  18. Организация школ здоровья для больных ишемической бо- лезнью сердца в практическом здравоохранении. Под ред. Р.Г.Оганова. М., 1993.
  19. Ощепкова Е.В., Дмитриев В.А., Гриднев В.И. и др. Трехлетний опыт работы регистра больных с острым коронарным синдромом в региональных сосудистых центрах и первичных со- судистых отделениях. Кардиологический вестник. 2012; 7 (19); 1.
  20. Приказ Минздравсоцразвития Российской Федерации от 22.11.04 №230 «Об утверждении стандарта медицинской по- мощи больным острым инфарктом миокарда».
  21. Репин А.Н., Лебедева Е.В., Сергиенко Т.Н., Карпов Р.С. Комплексная реабилитация пациентов с ишемической болезнью сердца в сочетании с тревожно-депрессивными расстрой- ствами. Кардиосоматика. 2010; 1: 51–6.
  22. Руда М.Я. и др. Российские рекомендации Общества специа- листов по неотложной кардиологии «Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы», 2014.
  23. Руда М.Я., Зыско А.П. Инфаркт миокарда. М.: Медицина, 1991.
  24. Смулевич А.Б. Депрессии при соматических и психических заболеваниях. М.: Медицинское информационное агентство, 2003.
  25. Сумин А.Н., Барбараш О.Л. Особенности кардиологической реабилитации в старших возрастных группах. Кардиосома- тика. 2012; 1: 38–43.
  26. Сыркин А.Л., Новикова Н.А., Терехин С.А. Острый коронарный синдром. М.: Медицинское информационное агентство, 2010.
  27. Чазова И.Е. и др. Российские рекомендации по диагностике и лечению АГ, 2013.
  28. Чумакова Г.Л., Киселева Е.В., Алешкевич В.В., Чурсина В.И. Вы- бор оптимальной интенсивности физических тренировок у больных с инфарктом миокарда и артериальной гипертони- ей. Сердечная недостаточность. 2002; 5: 5–9.
  29. Чукаева И.И., Орлова Н.В., Кисляк О.А. и др. Школы здоровья для больных сердечно-сосудистыми заболеваниями. Учебное пособие. М.: ГОУ ВПО РГМУ, 2011.
  30. Шальнова С.А., Деев А.Д., Оганов Р.Г. Распространенность ку- рения в России. Результаты обследования национальной пред- ставительной выборки населения. Проф. забол. и укрепл. здо- ровья. 1998; 3: 9–12.
  31. Agewall S, Cattaneo M, Collet JP et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disea- se and antithrombotic therapy. Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Eur Heart J 2013; 34: 1708–15.
  32. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatele ttherapy after acute coronary syndrome. N Engl J Med 2011; 365 (8): 699–708.
  33. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting-еzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial In- farction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332 (2): 80–5.
  34. American College of Sports Medicine (ACSM) Walking Equation ACSM’s Guidelines or Exercise Testing and Prescription; 2006.
  35. Anderson JL, Adams CD, Antman EM еt al. 2011 WRITING GROUP MEMBERS; ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Fo- cused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Gui- delines. Circulation. 2011; 123 (22): e. 627.
  36. Bangalore S, Qin J, Sloan S et al. What is optimal blood pressure in patients after acute syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin or atorVastatin Evaluation and infection Therapy-Thombolysis in Myocardial infarction (PROVE IT-TIMI) 22 trail. Circulation 2010; 122: 2142–51.
  37. Beck A. Cognitive Therapy of Depression. New York: Guilford Press; 1977.
  38. Belardinelli R. Benefits of the metabolic approach in cardiac re- habilitation Heart Metab 2008; 39: 25–8.
  39. Berkman LF, Blumenthal J, Burg M et al, for the Enhancing Reco- very in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on cli- nical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomised Trial. JAMA 2003; 289: 3106–16.
  40. Bertranda ME, Foxb KM, Remmec WJ et al. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: A subgroup analysis of the EUROPA trial Archives of Cardiovascular Disease. 2009; 102: 89–96.
  41. Braunwald E. Heart disease. A Textbook of Cardiovascular Medi- cine. W.B. Saunders Company. Philadelphia, London, Toronto, Sydney, Tokyo; 1996.
  42. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long- term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarc- tion: results of the Survival of Myocardial Infarction Long-term Eva- luation-2 (SMILE-2) study. Am Heart J 2003; 145 (1): 80–7.
  43. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153 (3): 445.e7–14.
  44. Borghi C et al. Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial in- farction (SMILE IV trial). JACC 2011; abstr.
  45. Borghi C, Marino P, Zardini P et al. Short-and long-term effects of early fosinopril administration in patients with acute anterior myo- cardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J 1998; 136 (2): 213–25.
  46. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fib- rillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429.
  47. Carney RM, Blumenthal JA, Freedland KE et al. Depression and la- te mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004; 66 (Suppl.): 466–74.
  48. Committee on Exercise and Cardiac Rehabilitation of the Co- uncil on Clinical Cardiology. Core components of cardiac rehabili- tation/secondary prevention programs. A statement for health pro- fessionals by the Committee on Exercise and Cardiac Rehabilita- tion of the Council on Clinical Cardiology. Circulation 2000; 102; 1069 (2007): 73.
  49. Cooper A, Skinner J, Nherera L et al. Clinical Guidelines and Evi- dence Review for Post Myocardial Infarction: Secondary prevention in primary and secondary care for patients following a myocardial infarction London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2007.
  50. Giannuzzi P, Saner H, Björnstad H et al. Mendes M, Cohen-Solal A, Dugmore L, Hambrecht R, Hellemans I, McGee H, Perk J, Vanhees L, Ve- ress G; Working Group on Cardiac Rehabilitation and Exercise Phy- siology of the European Society of Cardiology. Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur Heart J 2003; 24: 1273–8.
  51. Gulliksson M, Burell G, Vessby B. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recur- rent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care Project (SU- PRIM). Arch Intern Med 2011; 171: 134–40.
  52. Dawood N, Vaccarino V, Reid KJ et al. Predictors of smoking cessation after a myocardial infarction. The role of institutional smoking cessation programs in improving success. Arch Int Med 2008; 168: 1961–7.
  53. DeВusk R, Drory Y, Goldstein I et al. Management of sexual dys- function in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol 2000; 86: 175–81.
  54. Dickstein K, Kjekshus J. Effects of losartan captopril on mortality morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial In- farction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60.
  55. Drory Y, Shapira I, Fisman EZ, Pines A. Myocardial ischemia du- ring sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 855–7.
  56. Effect of nicorandil on coronary events in patients with stable an- gina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 2002; 359: 1269–75.
  57. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659–66.
  58. Field JM, Hazinski MF, Sayre MR et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S640–56.
  59. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS Guideline for the Diagnosis and Management of Pa- tients With Stable Ischemic Heart Disease JACC 2012; 60 (24): e44–164.
  60. Fourth International Study of Infarct Survival Collaborative Gro- up. ISIS-IV: a randomized factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85.
  61. Fox KA et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 2006; 333: 1091.
  62. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomi- sed, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
  63. Fuster V, Ryden LE, Cannom DS et al. 2011 ACCF/AHA/HRS focu- sed updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Asso- ciation Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Socie- ty. J Am Coll Cardiol 2011; 57: e101–e98.
  64. Frühbeck G, Toplak H, Woodward E et al. Тhe Executive Commit- tee of the European Association for the Study of Obesity Obesity: The Gateway to Ill Health – an EASO Position Statement on a Rising Pub- lic Health, Clinical and Scientific Challenge in Europe Obes Facts. 2013; 6: 117–20.
  65. Glassman AH, O’Connor CM, Califf RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701–9.
  66. Granger CB, Goldberg RJ, Dabbous O et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intem Med 2003; 163 (19): 2345–53.
  67. Green LA, Arbor A, Dickinson WP et al. AAFP Guideline for the De- tection and Management of Post–Myocardial Infarction Depression. Ann Fam Med 2009; 7:71–9. DOI: 10.1370/afm.918.
  68. Goble AJ, Hare DL, Macdonald PS et al. Effect of early programmes of high and low intensite exercise on physical performance after transmural acute myocardial infarction Br Heart J 1991; 65: 126–31.
  69. Cooper A, Skinner J, Nherera L et al. Clinical Guidelines and Evi- dence Review for Post Myocardial Infarction: Secondary prevention in primary and secondary care for patients following a myocardial infarction London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. NICE guideline Post MI Full Guideline 2007.
  70. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl tri- nitrate singly and together on 6 week mortality and ventricular func- tion after acute myocardial infarction. Lancet 1994; 343: 1115–22.
  71. Giuseppe MG, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Gui- delines for themanagement of arterial hypertension Eur Heart J 2013. doi:10.1093/eurheartj/eht151.
  72. Hassan Y, Kassab Y, Abd Aziz N et al. The impact of pharmacist- initiated interventions in improving acute coronary syndrome secon- dary prevention pharmacotherapy prescribing upon discharge. J Clin Pharm Ther 2013; 38 (2): 97–100.
  73. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoa- gulants in patients with non-valvular atrial fibrillation (EHRA) Prac- tical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Europace 2013; 15: 625–51.
  74. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187–92.
  75. Honig A, Kuyper AM, Schene AH et al. Treatment of postmyocardial infarction depressive disorder: a randomized, placebocontrolled trial with mirtazapine. Psychosom Med 2007; 69: 606–13.
  76. Iyengar SS, Rosano GMC. Effect Antianginal Drug in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial infarction. Am J Cardiovasc Drugs 2009; 9 (5); 293–7.
  77. James S, Roe M, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for noninvasive management: substudy from prospective randomized PLATelet inhi- bition and patient Outcomes (PLATO) trial. Br Med J 2011; 342: d3527.
  78. James PA, Oparil S, Carter BL et al. 2014 Evidence-Based Guideli- ne for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA. doi:10.1001/jama.2013.284427.
  79. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideli- ne for the Management of Patients With Atrial Fibrillation J Am Coll Cardiol 2014; doi: 10.1016/j.jacc.2014.03.022.
  80. Jensen MMD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Asso- ciation Task Force on Practice Guidelines and The Obesity Society published online November 12, 2013 Circulation. Print ISSN: 0009-7322. Online ISSN: 1524–4539 http://circ.ahajournals.org/content/ early/2013/11/11/01.cir.0000437739.71477.ee.citation
  81. Joliffe JA, Rees K, Taylor RS et al. Exercise-based rehabilitation for coronary heart disease, 2002. Oxford: Update Software.
  82. Joint British Societies’ consensus recommendations for the pre- vention of cardiovascular disease (JBS3) Heart 2014; 100: ii1–ii67.
  83. Kristensen S, Laut KG, Fajadet J et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J 2014; 35: 1957–70.
  84. Kostis JB, Jackson G, Rosen R et al. R. Sexual dysfunction and car- diac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313–21.
  85. Køber L, Torp-Pedersen C, Carlsen JE et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angio- tensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfuction after myocardial infarction. N Engl J Med 1995; 33: 1670–6.
  86. Leon AS, Franklin BA, Costa F et al. Cardiac rehabilitation and se- condary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardio- logy (Subcommittee on Exercise, Cardiac Rehabilitation, and Preven- tion) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the Ameri- can association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005; 111: 369–76.
  87. Levine GN, Steinke EE, Bakaeen FG et al. Sexual Activity and Car- diovascular Disease A Scientific Statement from the American Heart Association. Circulation 2012; 125: 1058–72.
  88. Lesperance F, Frasure-Smith N, Koszycki D et al. Effects of citalo- pram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367–79.
  89. Lip GY, Huber K, Andreotti F et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary – a Con- sensus Document of the European Society of Cardiology Working Gro- up on Thrombosis, endorsed by the European Heart Rhythm Associa- tion (EHRA) and the European Association of Percutaneous Cardio- vascular Interventions (EAPCI). Eur Heart J 2010; 31: 1311–8.
  90. Lyamina NP, Manukhina EB, Dovney F, Lyamina SV. Beneficial ef- fects of adaptation to hypoxia in patients with ischemic heart disease and extra systolic arrhythmias. J Mol Cell Cardiо 2007; 42 (Suppl. 1): 9–12.
  91. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hy- pertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34 (28): 2159–219.
  92. Marchioli R, Barzi F, Bomba E et al. Early protection against sud- den death by n-3 polyunsaturated fatty acids after myocardial in- farction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) – Pre- venzione. Circulation 2002; 105 (16): 1897–903.
  93. Martin BJ, Hauer T, Агепа R et al. Cardiac Rehabilitation Atten- dance and Outcomes in Coronary Artery Disease Patients. Circula- tion 2012; 26 (6): 677–87.
  94. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. ATLAS ACS 2–TIMI 51 Inve- stigators. N Engl J Med 2012; 366: 9–19.
  95. Möller J, Ahlbom A, Hulting J et al. Sexual activity as a trigger of myocardial infarction: a case-crossover analysis in the Stockholm Heart Epidemiology Programmer (SHEEP). Heart 2001; 86: 387–90.
  96. Montalescot G, Sechtem U, Achenbach S. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; doi:10.1093/eurheartj/eht296.
  97. Moser M, Olivier CB, Bode C. Triple antithrombotic therapy in cardiac patients: more questions than answers. Eur Heart J 2014; 35: 216–23.
  98. Moss AJ, Benhorin J. Prognosis and management after a first myo- cardial infarction. N Engl J Med 1990; 322: 743–53.
  99. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 4 (8): 803–69.
  100. Nahm ES, Blum K, Scharf B et al. Exploration of patients' readi- ness for an eHealth management program for chronic heart failure: a preliminary study. J Cardiovasc Nurs 2008; 23 (6): 463–71.
  101. Nehra A, Jackson G, Miner M et al. The Princeton III Consensus Recommendations for the Management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (8): 766–78.
  102. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA Gui- deline for the Management of ST-Elevation Myocardial Infarction.A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. / JACC 2013; 61 (4): e78–e140.
  103. Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet thera- py: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781–9.
  104. Ory MG, Peck BM, Browning C, Furjuoh SN. Lifestyle discussions during doctor-older patient interactions: the role of time in the medi- cal encounter. Med Gen Med 2007; 9 (4): 48.
  105. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfuction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77.
  106. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349 (20): 1893–906.
  107. Perk J, Backer GD, Gohlke H et al. European Guidelines on car- diovascular disease prevention in clinical practice (version 2012). Eur Heart J 2013; doi:10.1093/eurheartj/ehs092.
  108. Physical activity guidelines advisery committee (PAGAC)/Physi- cal activity guidelines advisery committee report, 2008, Washington DC, US, Department of health and human services, 2008.
  109. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldoste- rone blocker, in patients with left ventricular dysfunction after myo- cardial infarction. N Engl J Med 2003; 348 (14): 1309–21.
  110. Pitt B, White H, Nicolau J et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol 2005; 46: 425–31.
  111. Rea TD, Heckbert SR, Kaplan RC et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137 (6): 494–500.
  112. Rehabilitation after cardiovascular diseases with special em- phasis on developing country. A report of a WHO Committee. World Health Organ. Tech Rep Ser 1993; 831: 1–122.
  113. Rees K, Bennett P, West R et al. Psychological interventions for coro- nary heart disease. Cochrane Database of Systematic Reviews 2004; 2. Art No: CD002902. DOI: 10.1002/14651858. CD002920.pub2.
  114. Rognmo О, Moholdt T, Bakken H et al. Cardiovascular Risk of High-Versus Moderate-Intensity Aerobic Exercise in Coronary Heart Disease Patients. Circulation 2012; 126 (12): 1436–40.
  115. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopido- grel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEJM 2005; 352: 1179–89.
  116. Sakata Y, Nakatani D, Shimizu M et al. Oral treatment with nico- randil at discharge is associated with reduced mortality after acute myocardial infarction. J Cardiol 2012; 59: 14–21.
  117. Scrutinio D, Temporelli PL, Passantino A, Giannuzzi P. Long-term Secondary Prevention Programs After Cardiac Rehabilitation for the Reduction of Future Cardiovascular Events: Focus on Regular Physi- cal Activity Future Cardiol. 2009; 5 (3): 297–314.
  118. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Car- diology Foundation. J Am Coll Cardiol 2011; 58: 2432–46.
  119. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infraction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993; 342: 821–8.
  120. Steg PG, James SK, Atar D et al. ESC Guidelines for the manage- ment of acute myocardial infarction in patients presenting with ST- segment elevation. Eur. Heart J 2012; 33: 2569–619.
  121. Steinke EE, Jaarsma T, Barnason SA et al Sexual Counselling for Individuals With Cardiovascular Disease and Their Partners A Con- sensus Document From the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP) European Heart Journal2013July 29, doi:10.1093/eurheartj/eht270.
  122. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Gui- deline on the Treatment of Blood Cholesterol to Reduce Atherosclero- tic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Gui- delines Circulation 2013; http://circ.ahajournals.org/content/ear- ly/2013/11/11/01.cir.0000437738.63853.7a.citation.
  123. Taylor RS, Brown A, Ebrahim S et al. Exercise-based rehabilita- tion for patients with coronary heart disease: systematic review andmeta-analysis of randomized controlled trials. Am J Med 2004; 116: 682–92.
  124. Taylor CB, Youngblood ME Catellier D et al. Effects of antide- pressant medication on morbidity and mortality in depressed pati- ents after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792–8.
  125. Thompson DR, Webster RA, Cordle CJ et al. Specific sources and patterns of anxiety in male patients with first myocardial infarction. Br J Med Psychol 1987; 60: 343–48.
  126. Thomas RJ, King M, Lui K et al. AACVPR/ACCF/AHA 2010 update: performance measures on cardiac rehabilitation for referral to car- diac rehabilitation/secondary prevention services. Circulation 2010; 122: 1342–50.
  127. The GRACE Investigators, GRACE: a multinational registry of pa- tients hospitalized with acute coronary syndromes. Am Heart J 2001; 141: 190–9.
  128. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Car- diac Evaluation. Lancet 1999; 354: 9–12.
  129. Vandvik PO, Lincoff AM, Gore JM et al. Primary and Secondary Prevention of Cardiovascular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed American College of Chest Physici- ans Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl.): e637S–e68S.
  130. Working Group on Cardiac Rehabilitation and Exercise Physio- logy of the European Society of Cardiology. Position paper of the Wor- king Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology: Secondary prevention through car- diac rehabilitation. Eur Heart J 2003; 24: 1272–8.
  131. WHO. Rehabilitation of patients with cardiovascular disease. Re- port of WHO Expert Committee, 1964. WHO Technical Report Series No 270. Geneva: WHO.
  132. White book on physical and rehabilitation medicine in Europe, 2006. Ed: Gutenbrunner C, Ward AB, Chamberlain MA.
  133. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for at- rial fibrillation: antithrombotic therapy and prevention of thrombo- sis, 9th ed: American College of Chest Physicians Evidence-based Cli- nical Practice Guidelines. Chest 2012; 141 (Suppl. 2): e531S–e575S.
  134. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-conver- ting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investiga- tors. N Engl J Med 2000; 342 (3): 145–53.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
10. Список основной литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*